The DOI matches its Crossref record; 1 of the 1 references it cites were found in a registry or an index.
Intraperitoneal Administration of Autologous Tolerogenic Dendritic Cells for Refractory Crohn’s Disease: A Phase I Study
Abstract
BACKGROUND AND AIMS: Ex vivo-generated autologous tolerogenic dendritic cells [tolDCs] can restore immune tolerance in experimental colitis. The aim of this study was to determine the safety and tolerability of administration of autologous tolDCs in refractory Crohn's disease [CD] patients. METHODS: A phase-I, single-centre, sequential-cohorts, dose-range study was designed. Stable tolDCs were generated ex vivo from monocytes following a previously developed protocol, and administered by sonography-guided intraperitoneal injection. Six sequential refractory-CD cohorts were established: the first three cohorts received a single intraperitoneal injection of tolDCs at escalating doses [2 x 10(6)/5 x 10(6)/10 x 10(6)]; and the last three cohorts received three biweekly intraperitoneal injections at same escalating doses. Safety was sequentially evaluated. Patients were assessed from week 0 to 12 and followed up for 1-year period for safety. RESULTS: Nine patients were included. No adverse effects were detected during tolDC injection or follow-up. Three patients withdrew from the study due to CD worsening. Crohn's Disease Activity Index [CDAI] decreased from 274 [60] {mean (standard deviation [SD])} to 222 [113] [p = 0.3]; one [11%] patient reached clinical remission [CDAI < 150] and two [22%] clinical response [CDAI decrease ≥ 100]. Crohn's Disease Endoscopic Index of Severity [CDEIS] decreased from 18 [5] to 13 [8] [p = 0.4]; lesions improved markedly in three patients [33%]. Quality of life (inflammatory bowel disease questionnaire [IBDQ]) changed from 125 [27] to 131 [38] [p = 0.7]; remission [IBDQ at Week 12 ≥ 170] was reached in one [11%] case and response [IBDQ score increase ≥ 16] in two [22%]. CONCLUSIONS: Intraperitoneal administration of autologous tolDCs appears safe and feasible in refractory CD patients. Further studies should be developed to test clinical benefit, determine the optimal administration route and dose, and monitor the immune responses; See [www.eudract.ema.europa.eu, EudraCT number 2007-003469-42; www.aemps.gob.es number PEI 08-049].
Overview
The claims and statistics of this paper haven’t been checked yet.
Run the check — free, no account needed. It reads the open-access text and checks the sources it cites.
Integrity signals
Registry
Cites
Statistics
Verification
Claims the paper makes
The claims and statistics of this paper haven’t been checked yet.
Run the check — free, no account needed. It reads the open-access text and checks the sources it cites.
Self-check
Percentages, sums and reported differences re-computed from the paper’s own numbers.
The self-check needs the paper’s full text.
Citations
Cites
Duijvestein, M., Vos, A. C. W., Roelofs, H., Wildenberg, M. E., Wendrich, B. B., Verspaget, H. W., Kooy-Winkelaar, E. M. C., Koning, F., Zwaginga, J. J., Fidder, H. H., et al. (2010) · Gut · doi:10.1136/gut.2010.215152 · Cited by 622
Cited by
Vitamin D and Immune Regulation: Antibacterial, Antiviral, Anti‐Inflammatory
L Bishop, E., Ismailova, A., Dimeloe, S., Hewison, M., & White, J. H. (2021) · JBMR Plus · doi:10.1002/jbm4.10405 · Cited by 392
Autologous tolerogenic dendritic cells for rheumatoid and inflammatory arthritis
Bell, G. M., Anderson, A. E., Diboll, J., Reece, R., Eltherington, O., Harry, R. A., Fouweather, T., MacDonald, C., Chadwick, T., McColl, E., et al. (2017) · Annals of the Rheumatic Diseases · doi:10.1136/annrheumdis-2015-208456 · Cited by 315
Tolerogenic Dendritic Cells in Autoimmunity and Inflammatory Diseases
Morante-Palacios, O., Fondelli, F., Ballestar, E., & Martínez-Cáceres, E. M. (2021) · Trends in Immunology · doi:10.1016/j.it.2020.11.001 · Cited by 263
Metadata
- Authors
- Jauregui-Amezaga, A., Cabezón, R., Ramírez-Morros, A., España, C., Rimola, J., Bru, C., Pinó-Donnay, S., Gallego, M., Masamunt, M. C., Ordás, I., Lozano, M., Cid, J., Panés, J., Benítez-Ribas, D., & Ricart, E.
- Venue
- Journal of Crohn's and Colitis
- Publisher
- Oxford University Press (OUP)
- Published
- 2015-08-24
- Volume
- 9
- Issue
- 12
- Pages
- 1071-1078
- ISSN
- 1873-9946 (ISSN-L)
- 1876-4479
- OpenAlex
- W2122532904
- Cited by
- 167
- References
- 1
- FWCI
- 9.05
- Type
- journal article
- Language
- en
- Open access
- closed
About these checks
Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.
Statistics and arithmetic are recomputed, not judged.
Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.
What counts as a claim ›How we measure confidence ›How we check this ›
Are you an author, or do you see a problem with this page? Request a review
How to cite
Cite CoChat for the checks on this page, and the paper for its own findings.
- This page
- CoChat. (2026). Citation check: Intraperitoneal Administration of Autologous Tolerogenic Dendritic Cells for Refractory Crohn’s Disease: A Phase I Study. https://app.cochat.ai/papers/10.1093/ecco-jcc/jjv144
- The paper
- Jauregui-Amezaga, A., Cabezón, R., Ramírez-Morros, A., España, C., Rimola, J., Bru, C., Pinó-Donnay, S., Gallego, M., Masamunt, M. C., Ordás, I., Lozano, M., Cid, J., Panés, J., Benítez-Ribas, D., & Ricart, E. (2015). Intraperitoneal Administration of Autologous Tolerogenic Dendritic Cells for Refractory Crohn’s Disease: A Phase I Study. Journal of Crohn's and Colitis. https://doi.org/10.1093/ecco-jcc/jjv144
Data sources
Bibliographic data: Semantic Scholar, OpenAlex, Crossref.
Contains information from the Semantic Scholar Academic Graph Datasets, made available under the ODC Attribution License (ODC-BY 1.0).
Semantic Scholar’s data is described in: Kinney, R., et al. (2023). The Semantic Scholar Open Data Platform. arXiv:2301.10140.